Volume 92 Issue 27 | p. 17 | Concentrates
Issue Date: July 7, 2014

Roche Will Acquire Oncology Drug Company Seragon

Department: Business
Keywords: biopharmaceuticals, oncology, acquisitions

Roche’s Genentech unit will spend $725 million to buy Seragon Pharmaceuticals, a privately held biotech firm in San Diego. Founded in 2013, Seragon is developing selective estrogen receptor degraders (SERDs) for treating hormone receptor-positive cancers. Genentech will get Ser­agon’s collection of small-molecule SERDs, including one targeting breast cancer that is in Phase I development. Genentech could pay up to $1 billion more should Seragon’s candidates hit certain milestones.

. . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society